Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Anticoagulant: the invisible yet essential ally of therapeutic apheresis
At first glance, one might think it’s normal saline.
Pearling drops, a steady flow, almost reassuring. And yet… what you’re seeing is far more than a simple solution.
It is an anticoagulant, a fundamental pillar of therapeutic apheresis procedures: ACD-A (Acid Citrate Dextrose – Solution A).
Its mission is clear and essential: to prevent blood from clotting in the extracorporeal circuit during apheresis.
Without it, safe blood processing would simply not be possible.
In practice, anticoagulation ratios can be adjusted depending on the procedure. But not all procedures are equal in terms of duration.
Plasma exchange or red cell exchange typically last 1 to 2 hours.
However, during hematopoietic stem cell collections or lymphocyte collections for CAR-T cell manufacturing, patients may remain connected to the machine for 3 to 6 hours, sometimes processing up to three mass of total blood volumes to achieve the required cell yield.
The specificity of ACD-A?
Citrate chelates calcium, which may lead to hypocalcemia: perioral tingling, metallic taste, chills, tremors… and potentially more severe symptoms if not anticipated.
This is why true expertise in apheresis is essential.
Optimizing a procedure means finding the right balance between collection efficiency, clinical safety, and patient comfort.
It requires close collaboration between nurses, physicians… and industry partners.
Because in apheresis, every single drop matters.”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 15:24Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
-
Mar 26, 2026, 15:19Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care
-
Mar 26, 2026, 15:19Attilio Cotroneo: Updated Evidence-Based Recommendations for the Management of BTAI
-
Mar 26, 2026, 15:14Rodrigo Assar: Thrombosis Risk Prediction in Pediatric Central Lines
-
Mar 26, 2026, 14:48Alfonso J. Tafur: We Need to Rethink What Drives Disparities in Blood Clot Outcomes
-
Mar 25, 2026, 16:00Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
-
Mar 25, 2026, 15:56Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
-
Mar 25, 2026, 15:52Indunil Karunarathna: Kawasaki Disease at the Intersection of Immunology, Cardiology, and Vascular Biology
-
Mar 25, 2026, 15:48Micah Grey: Reflecting on an Incredible Experience at the THSNA Congress